Korean J Obstet Gynecol.  2002 Nov;45(11):2057-2061.

Treatment of Advanced-Stage Sertoli-Leydig Cell Tumor (SLCT): A Clinicopathologic Study of 1 Case

• Kim JS
• Yoon YM
• Yoo CW
• Jun HA
• Kim HB
• Lee GY
• Kang SW

Abstract

Sertoli-Leydig cell tumors belong to the group of sex-cord stromal tumors of the ovary. They account for less than 0.5% of all ovarian tumor. They occur predominantly at premenopausal women and rarely at postmenopausal and prepubertal. Most common symptom is menstrual disorder including vaginal bleeding. This symptom is the results of excessive testosterone production of Leydig cell. Masculinization is occasionally accompanied by this symptom. but approximately 50% of patients with SLCT have no endocrine manifestations. Prognosis prove generally favorable with 5-year survival rate of 70-90%. Recurrence is rare.The majority of these tumors are benign and are unilaterally (97-98%) localized. Surgery varies with patient age, tumor stage, and differentiation from unilateral salpingo-oophorectomy to bilateral salpingo-oophorectomy and total hysterectomy concomitant with pelvic lymph node dissection. Herewith, we experienced a case of treatment advanced-stage Sertoli-Leydig cell tumor with poorly differentiation in that is ascitic and metastatic in a 53 years old menopause woman who has no virilizing symptom. After all the tumor has resulted in fatal outcome despite of surgery and aggressive chemotherapy. Therefore we present it with review of literature.

Keyword

Sertoli-Leydig Cell Tumor

MeSH Terms

Drug Therapy
Fatal Outcome
Female
Humans
Hysterectomy
Lymph Node Excision
Menopause
Middle Aged
Ovary
Prognosis
Recurrence
Sertoli-Leydig Cell Tumor*
Survival Rate
Testosterone
Uterine Hemorrhage
Testosterone